CanSino Biologics Inc (688185) Fair Value & Analysis
Healthcare · CN · Market cap 12.7B CNY
Fair value as of: Jun 24, 2026
From 16 valuation models · updated 7 days ago
Share price −20.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥50.00 – ¥92.36 · fair‑value band ¥7.93 – ¥14.72 · the ¥50.00 price screens above the ¥11.32 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
CanSino Biologics Inc (688185) currently trades at ¥50.00, while our model-based Fair Value estimate is ¥11.32 — implying the stock looks roughly 77.4% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, CanSino Biologics Inc generated revenue of 1.1B CNY at a net margin of -0.1%. Revenue grew 38.7% year over year. Net debt stands at 55.8M CNY. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CanSino Biologics Inc reported revenue of ¥1.1B in FY2025 versus ¥4.3B in FY2021, a compound −29.4%/yr. Reported net income was ¥27.9M in FY2025, compounding −65.3%/yr from FY2021.
Is 688185 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CanSino Biologics Inc (688185) undervalued?
What is the fair value of 688185?
What is the quality score of 688185?
What is the revenue of CanSino Biologics Inc (688185)?
What is the net profit margin of 688185?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.